Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioNet heads for potential $150m IPO (initial public offering):

This article was originally published in Clinica

Executive Summary

Heart monitor developer CardioNet has filed for an initial public offering which the company claims could have a maximum price offering approaching $150m. The San Diego, California-based firm did not disclose the expected number of shares to be offered but did state that it would use the proceeds to pay an outstanding term loan and a success fee connected to the IPO to Silicon Valley Bank. Funds will also be channelled towards increasing sales and marketing capabilities for the company's CardioNet System, which monitors and diagnoses heart rhythm disorders. Over the last three years, the company has cut its net loss considerably, posting a deficit of $6.7m in 2006, down 68% from a loss of $21m in 2004. CardioNet plans to list on the Nasdaq under the ticker symbol "BEAT".

You may also be interested in...

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.

Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts